**Supplemental Materials**

**Supplemental Table 1.** Adverse events observed and adjudicated as possibly, probably or definitely related to therapy (n = 19).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **CTCAE 3.0 Toxicity Grade** | | | | |
|  | **1** | **2** | **3** | **4** | **3/4** |
| **Hematologic Adverse Events** |  |  |  |  |  |
| Hemoglobin | 1 (5.3%) | 1 (5.3%) | 0 | 0 | 0 |
|  |  |  |  |  |  |
| **Non-Hematologic Adverse Events** |  |  |  |  |  |
| Fatigue | 6 (31.6%) | 2 (10.5%) | 0 | 0 | 0 |
| Pain | 5 (26.3%) | 2 (10.5%) | 0 | 0 | 0 |
| Nausea | 3 (15.8%) | 2 (10.5%) | 0 | 0 | 0 |
| AST-SGOT | 2 (10.5%) | 0 | 1 (5.3%) | 0 | 1 (5.3%) |
| Hypophosphatemia | 1 (5.3%) | 2 (10.5%) | 0 | 0 | 0 |
| Bilirubin | 2 (10.5%) | 1 (5.3%) | 0 | 0 | 0 |
| Alkaline Phosphatase | 3 (15.8%) | 0 | 0 | 0 | 0 |
| Alopecia | 3 (15.8%) | 0 | 0 | 0 | 0 |
| ALT-SGPT | 0 | 1 (5.3%) | 1 (5.3%) | 0 | 1 (5.3%) |
| Lipase | 0 | 1 (5.3%) | 1 (5.3%) | 0 | 1 (5.3%) |
| Rash | 0 | 1 (5.3%) | 1 (5.3%) | 0 | 1 (5.3%) |
| Hyponatremia | 1 (5.3%) | 0 | 1 (5.3%) | 0 | 1 (5.3%) |
| Amylase | 0 | 2 (10.5%) | 0 | 0 | 0 |
| Hypoalbuminemia | 1 (5.3%) | 1 (5.3%) | 0 | 0 | 0 |
| Anorexia | 2 (10.5%) | 0 | 0 | 0 | 0 |
| Diarrhea | 2 (10.5%) | 0 | 0 | 0 | 0 |
| Skin – Other | 2 (10.5%) | 0 | 0 | 0 | 0 |
| Hepatic – Elevated pancreatic enzymes | 0 | 0 | 1 (5.3%) | 0 | 1 (5.3%) |
| Constitutional – Appetite loss | 0 | 1 (5.3%) | 0 | 0 | 0 |
| Dyspepsia | 0 | 1 (5.3%) | 0 | 0 | 0 |
| Edema | 0 | 1 (5.3%) | 0 | 0 | 0 |
| Ocular – Visual changes | 0 | 1 (5.3%) | 0 | 0 | 0 |
| Pruritis | 0 | 1 (5.3%) | 0 | 0 | 0 |
| Bronchospasm | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Cardiac - Palpitations | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Constipation | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Dry Skin | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Fever without Neutropenia | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Hyperkalemia | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Hypocalcemia | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Insomnia | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Nail Changes | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Sensory Neuropathy | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Taste Disturbance | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Urinary Frequency | 1 (5.3%) | 0 | 0 | 0 | 0 |
| Urinary Incontinence | 1 (5.3%) | 0 | 0 | 0 | 0 |